Aperio, the global leader in providing digital pathology solutions that improve patient care, today announced that it has appointed Thomas Bologna, President & Chief Executive Officer of Orchid Cellmark, Inc. (NASDAQ: ORCH), a leading service provider of DNA identity testing, to its Board of Directors. Last week, Aperio announced that healthcare veteran David Schlotterbeck had also joined its Board.
